AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Elanco Animal Health to Replace Sarepta Therapeutics in S&P MidCap 400; Sarepta Therapeutics to Replace Brookline Bancorp in S&P SmallCap 600.
ByAinvest
Wednesday, Aug 27, 2025 1:21 am ET1min read
Elanco Animal Health will replace Sarepta Therapeutics in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp in the S&P SmallCap 600, effective before the opening of trading on Tuesday, September 2.
Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASDAQ: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASDAQ: BRKL) in the S&P SmallCap 600, effective before the opening of trading on Tuesday, September 2. The changes are part of a broader rebalancing of the indices, reflecting the ongoing evolution of the financial markets.Elanco Animal Health, a leading animal health company, is set to enter the S&P MidCap 400, a benchmark index for mid-cap stocks. The company's inclusion signals confidence in its financial performance and growth prospects. Meanwhile, Sarepta Therapeutics, a biopharmaceutical company, will join the S&P SmallCap 600, a smaller-cap index. This move underscores Sarepta's potential for growth and innovation in the biotechnology sector.
The changes come amid a series of corporate actions. Berkshire Hills Bancorp Inc. (XNYS: BHLB), a constituent of the S&P SmallCap 600, is acquiring Brookline Bancorp Inc. in a deal expected to be completed soon. Post-merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE: BBT).
These index changes are part of a broader strategy by S&P Dow Jones Indices to ensure that their benchmarks accurately reflect the current financial landscape. The S&P MidCap 400 and S&P SmallCap 600 are widely followed indices, and their composition can influence investment decisions.
For more information about S&P Dow Jones Indices and the changes, please visit [www.spdji.com](http://www.spdji.com).
References:
[1] https://www.nasdaq.com/press-release/elanco-animal-health-set-join-sp-midcap-400-sarepta-therapeutics-join-sp-smallcap-600
[2] https://www.morningstar.com/news/pr-newswire/20250826ny59846/elanco-animal-health-set-to-join-sp-midcap-400-sarepta-therapeutics-to-join-sp-smallcap-600
[3] https://seekingalpha.com/news/4489372-elanco-animal-health-set-to-join-sp-midcap-400-sarepta-to-join-sp-smallcap-600
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet